The Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) voted on Thursday to add peptides to the list of substances that compounding pharmacies are permitted to create. This decision was made despite concerns from agency scientists regarding the lack of demonstrated benefits associated with these substances. The committee reviewed public comments and presentations from FDA staff regarding specific peptides, including BPC-157, KPV, TB-500, and MOTS-C.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Panel Votes to Include Peptides in Compounding List
The FDA's Pharmacy Compounding Advisory Committee voted to allow compounding pharmacies to create peptides, despite opposition from agency scientists about their benefits. The decision followed a review of public comments and presentations on specific peptides.
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
Neutral Headline
FDA Panel Votes to Include Peptides in Compounding List